Week In Review: Fosun Signs $125 Million Deal For Ardelyx IBS Treatment

Fosun Pharma obtained China rights to tenapanor, an Ardelyx treatment for irritable bowel syndrome with constipation (IBS-C), in a $125 million agreement. Tenapanor is also expected to treat hyperphosphatemia related to chronic kidney disease.